LCN2 and familial pancreatic carcinoma: In their systematic review, Roli et al. [14] reported a high heterogeneity of NGAL in pancreatic cancer with a pooled AUC of 0.84, a pooled sensitivity (Se) of 61% (I2 = 90.6%), and a pooled specificity (Sp) of 77% (I2 = 66.6%).